Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor
Tóm tắt
Previously, we reported that adoptively transferred perforin k/o (PKO), and IFN-γ k/o (GKO), or perforin/IFN-γ double k/o (PKO/GKO) effector T cells mediated regression of B16BL6-D5 (D5) pulmonary metastases and showed that TNF receptor signaling played a critical role in mediating tumor regression. In this report we investigated the role of lymphotoxin-α (LT-α) as a potential effector molecules of tumor-specific effector T cells. Effector T cells were generated from tumor vaccine-draining lymph node (TVDLN) of wt, GKO, LT-α deficient (LKO), or PKO/GKO mice and tested for their ability to mediate regression of D5 pulmonary metastases in the presence or absence of LT-βR-Fc fusion protein or anti-IFN-γ antibody. Chemokine production by D5 tumor cells was determined by ELISA, RT-PCR and Chemotaxis assays. Stimulated effector T cells from wt, GKO, or PKO/GKO mice expressed ligands for LT-β receptor (LT-βR). D5 tumor cells were found to constitutively express the LT-βR. Administration of LT-βR-Fc fusion protein completely abrogated the therapeutic efficacy of GKO or PKO/GKO but not wt effector T cells (p < 0.05). Consistent with this observation, therapeutic efficacy of effector T cells deficient in LT-α, was greatly reduced when IFN-γ production was neutralized. While recombinant LT-α1β2 did not induce apoptosis of D5 tumor cells in vitro, it induced secretion of chemokines by D5 that promoted migration of macrophages. The contribution of LT-α expression by effector T cells to anti-tumor activity in vivo was not discernable when wt effector T cells were studied. However, the contribution of LT-β R signaling was identified for GKO or PKO/GKO effector T cells. Since LT-α does not directly induce killing of D5 tumor cells in vitro, but does stimulate D5 tumor cells to secrete chemokines, these data suggest a model where LT-α expression by tumor-specific effector T cells interacts via cross-linking of the LT-βR on tumor cells to induce secretion of chemokines that are chemotactic for macrophages. While the contribution of macrophages to tumor elimination in our system requires additional study, this model provides a possible explanation for the infiltration of inate effector cells that is seen coincident with tumor regression.
Tài liệu tham khảo
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002, 298: 850-854. 10.1126/science.1076514.
Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002, 99: 16168-16173. 10.1073/pnas.242600099.
Winter H, Hu HM, Urba WJ, Fox BA: Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol. 1999, 163: 4462-4472.
Winter H, Hu HM, McClain K, Urba WJ, Fox BA: Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol. 2001, 166: 7370-7380.
Poehlein CH, Hu HM, Yamada J, Assmann I, Alvord WG, Urba WJ: TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol. 2003, 170: 2004-2013.
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998, 95: 7556-7561. 10.1073/pnas.95.13.7556.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410: 1107-1111. 10.1038/35074122.
Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002, 13: 95-109. 10.1016/S1359-6101(01)00038-7.
Barth RJJ, Mule JJ, Spiess PJ, Rosenberg SA: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med. 1991, 173: 647-658. 10.1084/jem.173.3.647.
Hu HM, Urba WJ, Fox BA: Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 1998, 161: 3033-3041.
Aruga A, Aruga E, Cameron MJ, Chang AE: Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J Leukoc Biol. 1997, 61: 507-516.
Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE: Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol. 1997, 159: 664-673.
Aruga A, Shu S, Chang AE: Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother. 1995, 41: 317-324. 10.1007/BF01517220.
Winter H, Hu HM, Poehlein CH, Huntzicker E, Osterholzer JJ, Bashy J: Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology. 2003, 108: 409-419. 10.1046/j.1365-2567.2003.01596.x.
Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA: T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol. 2000, 165: 7116-7124.
Plautz GE, Mukai S, Cohen PA, Shu S: Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol. 2000, 165: 3656-3662.
Browning JL, Ngam-ek A, Lawton P, DeMarinis J, Tizard R, Chow EP: Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell. 1993, 72: 847-856. 10.1016/0092-8674(93)90574-A.
Ware CF, VanArsdale TL, Crowe PD, Browning JL: The ligands and receptors of the lymphotoxin system. Curr Top Microbiol Immunol. 1995, 198: 175-218.
Gramaglia I, Mauri DN, Miner KT, Ware CF, Croft M: Lymphotoxin alphabeta is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation. J Immunol. 1999, 162: 1333-1338.
Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, Kwon BS: LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest. 1998, 102: 1142-1151.
Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL: LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity. 1998, 8: 21-30. 10.1016/S1074-7613(00)80455-0.
Rooney IA, Butrovich KD, Glass AA, Borboroglu S, Benedict CA, Whitbeck JC: The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem. 2000, 275: 14307-14315. 10.1074/jbc.275.19.14307.
Browning JL, Miatkowski K, Sizing I, Griffiths D, Zafari M, Benjamin CD: Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J Exp Med. 1996, 183: 867-878. 10.1084/jem.183.3.867.
Hehlgans T, Mannel DN: Recombinant, soluble LIGHT (HVEM ligand) induces increased IL-8 secretion and growth arrest in A375 melanoma cells. J Interferon Cytokine Res. 2001, 21: 333-338. 10.1089/107999001300177529.
Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B: A lymphotoxin-beta-specific receptor. Science. 1994, 264: 707-710. 10.1126/science.8171323.
Force WR, Walter BN, Hession C, Tizard R, Kozak CA, Browning JL: Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression. J Immunol. 1995, 155: 5280-5288.
Murphy M, Walter BN, Pike-Nobile L, Fanger NA, Guyre PM, Browning JL: Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ. 1998, 5: 497-505. 10.1038/sj.cdd.4400374.
Degli-Esposti MA, Davis-Smith T, Din WS, Smolak PJ, Goodwin RG, Smith CA: Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. J Immunol. 1997, 158: 1756-1762.
Mackay F, Browning JL, Lawton P, Shah SA, Comiskey M, Bhan AK: Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology. 1998, 115: 1464-1475. 10.1016/S0016-5085(98)70025-3.
Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, Lassmann H: TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain. 2000, 123: 2005-2019. 10.1093/brain/123.10.2005.
Guo Z, Wang J, Meng L, Wu Q, Kim O, Hart J: Cutting edge: membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection. J Immunol. 2001, 167: 4796-4800.
Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA: Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med. 2001, 193: 1327-1332. 10.1084/jem.193.11.1327.
Lucas R, Tacchini-Cottier F, Guler R, Vesin D, Jemelin S, Olleros ML: A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection. Eur J Immunol. 1999, 29: 4002-4010. 10.1002/(SICI)1521-4141(199912)29:12<4002::AID-IMMU4002>3.0.CO;2-S.
Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF: LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2000, 164: 4105-4110.
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem. 1999, 274: 13733-13736. 10.1074/jbc.274.20.13733.
Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, Kronenberg M: Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol. 2001, 167: 6330-6337.
Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, Flies D: Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med. 2000, 6: 283-289. 10.1038/73136.
Schrama D, thor Straten P, Fischer WH, McLellan AD, Brocker EB, Reisfeld RA: Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity. 2001, 14: 111-121. 10.1016/S1074-7613(01)00094-2.
Fu YX, Chaplin DD: Development and maturation of secondary lymphoid tissues. Annu Rev Immunol. 1999, 17: 399-433. 10.1146/annurev.immunol.17.1.399.
Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD: A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000, 406: 309-314. 10.1038/35018581.
Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y: Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004, 5: 141-149. 10.1038/ni1029.
Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MAJ: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999, 398: 718-723. 10.1038/19546.
Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR: Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med. 1999, 190: 1813-1824. 10.1084/jem.190.12.1813.
Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M: The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest. 2001, 108: 1307-1314. 10.1172/JCI200112877.
Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE: Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 1996, 3: 39-47.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004, 351: 2159-2169. 10.1056/NEJMoa041869.
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003, 348: 203-213. 10.1056/NEJMoa020177.